Therapeutic gene

What are your views on Gene Therapy?

Posted on Updated on

We used to think that our fate was in our stars, but now we know that, in large measure, our fate is in our genes, “quotes James Watson.

This fate that Watson is talking about is contained in our genes, and deals with a new technique, GENE THERAPY.

gdfgGene therapy is an innovative way to fix genetic problem from the source. By adding a corrected copy of a defective gene, gene therapy promises to help diseased tissues and organs work properly. This approach is different from traditional drug-based approaches, which may treat symptoms but not the underlying genetic problems.

The treatment sounds magical, but the complexity of designing and delivering arises. The safety issues slowed the progress, following events like death of Jess Gelsinger, who died in 1999 just weeks after receiving an experimental gene therapy in a clinical trial being conducted by the University of Pennsylvania.

Although gene therapy is a promising treatment option for a number of diseases, the technique remains risky and is still under study to make sure that it will be safe and effective.

Also some genetic disorders are rare in nature affecting 1 in million. For such patients, Gene therapy can be a miracle but high cost of developing a treatment can make it unappealing for the pharmaceutical companies. With a limited number of patients to recover those expenses from, developers may never earn money from treating such rare genetic disorders. And some patients may never be able to afford them.

The first milestone in gene therapy, Gendicine, developed by Shenzhen SiBiono GeneTech was approved in China in 2003 for the treatment of head and neck cancers and the biggest watershed moment was Glybera, a gene therapy for lipoprotein lipase deficiency, launched in Germany at a price of more than 1 million euros ($1.1 million).

Meanwhile, companies like bluebird bio and Spark Therapeutics generated impressive clinical data with programmes of their own.

The success has generated renewed interest from both private and public equity investors as well as pharmaceutical companies, such as Bayer and Sanofi, which have willingly provided much-needed resources to companies working in the field in the form of financing and partnerships, helping to drive what could turn out to be a virtuous circle of success.

DelveInsight Gene Therapy Reports

DelveInsight’s Reports have already established a reputation of offering the affordable and comprehensive industry coverage and “on-the-ground” analysis in virtually every region of the world. These reports provide complete information for over 300 gene therapies which are in the pipeline for various therapy areas like; Oncology, Genitourinary, Dermatology, Central nervous system, Genetic Disorders, Hematological disorders, Metabolic disorders, Ophthalmology, Cardiovascular disease, Respiratory , Immunology, and many more…

DelveInsight’s Gene Therapy Reports cover the entire gene therapy market scenario including technology assessments, licensing opportunities, collaborations, market trends, pipeline coverage and competitive landscape. The report essentially provides DelveInsight’s proprietary market and pipeline analytics which identifies the front runners of all therapeutic areas. It also identifies the potential market movers and future regulatory landscape. These reports are designed to provide the clients with the means to out produce their competitors by developing a product that makes history.

For more info on Gene Therapy Reports for various Therapeutic areas contact us at: info@delveinsight.com.

By Rashi Aggarwal, Associate Analyst, DelveInsight

Please give your views on Gene Therapy and lets discuss about its potential in the market.

Advertisements

Break the Gene Therapy Barrier with DelveInsight’s Gene Therapy Reports

Posted on Updated on

Gene Therapy: The Future is here!

Scientific research and clinical trials aren’t glamorous, but they are essential for effective treatments and perhaps ultimately a cure for various debilitating diseases like cancer etc. Gene therapy’s potential to revolutionize medicine in the future is exciting, and one day it may be possible to treat an unborn child for a genetic disease even before symptoms appear.

About Gene Therapy

Gene Therapy involves using genes as medicines by transferring a therapeutic gene through a genetically engineered vector into the targeted cells of a patient to repair an unhealthy gene thus help in curing disease by synthesizing correct proteins. Put simply, it introduces a “good” gene into a person who has a disease caused by a “bad” gene.

Gene Therapy: The Past

Gene therapy has had rather a bad decade as it got off with two unapproved trials in the early 70s and early 80s in which first one was an attempt made to treat two young girls with arginase deficiency syndrome using in vivo gene therapy with wild-type Shope papilloma virus in order to replace the missing arginase enzyme in the patients and the second one was ex vivo gene therapy for ß-thalassemia, a bone marrow transplant using marrow cells treated with a ß-globin-containing plasmid, again in two patients. Unfortunately in neither case was any real follow-up reported, since both trials were stopped. The final blow to Gene therapy field came in September 1999 with the widely publicized death of an eighteen-year-old man undergoing gene therapy for a liver disease at the University of Pennsylvania, an event that brought the scrutiny of the press onto the world of gene therapy.

But at the turn of the millennium, through the year 2000, reports of the first successful trials began to be heard indicating that real success may be just around the corner: factor IX for hemophilia, transduced stem cells for X-linked SCID, and oncolytic vectors etc. In the ten year cycle of failed clinical trials the researchers learned from their mistakes and developed much more realistic approach and solutions to many of the problems which led to major clinical and commercial successes.

Gene Therapy: The Present Scenario

The past two decades have seen significant increase in the companies coming up with gene therapies for various therapeutic areas. The human clinical trials are majorly performed for the oncology indications. However, the market for gene therapy is currently in the experimental stages due the risk involved with the use of genes designed in laboratory growth as well as the regulatory approval of products which are currently in clinical trials resulting in only three drugs hitting the market in past decade. Inspite of this, Gene therapy has proved to be a promising approach for many incurable diseases with many promising therapies in phase III clinical trials.

Gene Therapy: The Market Scenario

Many companies have started investing in and researching on gene therapy due to its promising effects. A growing number of Big Pharma companies are partnering in drug development with innovation-rich biotech firms. Large Pharmaceutical and Biotechnology giants, such as Novartis, GlaxoSmithKline, Sanofi etc., are operating in the gene therapy domain. Moreover recent academic and industry partnerships for example between Celgene Corporation and Baylor College of Medicine, GSK and the Roswell Park Cancer Institute etc., are driving new gene therapy research. The industry’s collective pipeline is brimming with 300+ drugs of which oncology collectively accounts for 29 % of gene therapies in pipeline. Despite of high cost involved recent years have seen many companies coming up for the treatment of deadly diseases. The global market opportunities for gene therapy have risen drastically and continue to be great area of interest for many companies globally.

DelveInsight’s Gene Therapy Reports

DelveInsight’s Gene Therapy Reports cover the entire gene therapy market insights including technology assessments, licensing opportunities, collaborations, market trends, pipeline coverage and competitive landscape. The report essentially provides DelveInsight’s proprietary market and pipeline analytics which identifies the front runners of all therapeutic areas. It also identifies the potential market movers and future regulatory landscape.

The Report insight covers therapy areas like; Oncology, Central nervous system, Genetic Disorders, Hematological disorders, Metabolic disorders, Ophthalmology, Cardiovascular disease, Respiratory and Immunology and many more…

Get the First Mover Advantage in “The Big Value” Gene Therapy Market

Posted on Updated on

Drive your Research towards a Brighter Future with DelveInsight!

What do you feel when you see, cancer is getting cured by replacing the faulty or missing gene with the functional gene so that they can produce a protein to repair the anomaly responsible for the disease.

Awesome Innovation Right!Pre_Launch

DelveInsight is proud to announce the Pre-Launch of its Gene Therapy reports. These Reports are the outcome of very best analytical abilities and diligent market research amalgamated with opinions of gene therapy industry experts.

Are you an active Player in Gene Therapy! Get the first mover Advantage. Out produce everyone around you and develop a product that will make history!

Emerging Role of Gene Therapy

Every day we see the impact of innovation. Of most of the innovation delivered, Gene therapy is the biggest innovation. The scientific society has seen many transformations in past two decades with respect to gene therapy market. It has become an upcoming research area in 21st century with the industry’s collective pipeline brimming with therapies close to 300. Gene Therapy is preferred over drugs and surgery as it’s a onetime treatment which restores natural body function and did not just offer a short-term fix.

Pic (3)

Gene Therapy Research Companies and their Roles

Many companies have started investing in and researching on gene therapy due to its promising effects. A growing number of Big Pharma companies are partnering in drug development with innovation-rich biotech firms. Large Pharmaceutical and Biotechnology giants, such as Novartis, GlaxoSmithKline, Sanofi etc., are operating in the gene therapy domain. Moreover recent academic and industry partnerships for example between Celgene Corporation and Baylor College of Medicine, GSK and the Roswell Park Cancer Institute etc., are driving new gene therapy research.

Pic (6)

Gene Therapy Market Outlook

Gene Therapy involves using genes as medicines by transferring a therapeutic gene through a genetically engineered vector into the targeted cells of a patient to repair an unhealthy gene thus help in curing disease by synthesizing correct proteins. It involves the administration of DNA or RNA to modify the expression of genes or correct abnormal genes and is widely used in curing several disorders related to Oncology, Metabolic, Central Nervous system and Genetic etc., with oncology collectively accounting for 29 % of gene therapies in pipeline. However, the market for gene therapy is currently in the experimental stages due the risk involved with the use of genes designed in laboratory growth as well as the regulatory approval of products which are currently in clinical trials resulting in just three drugs hitting the market in past decade. Inspite of this, Gene Therapy has proved to be a promising approach for many incurable diseases.

Pic (2)

Pic (1)

What DelveInsight Have for You!

DelveInsight is launching its Gene Therapy Reports in coming week. DelveInsight Gene Therapy Reports cover the entire gene therapy market insights including technology assessments, licensing opportunities, collaborations, market trends, pipeline coverage and competitive landscape. The report essentially provides DelveInsight’s proprietary market and pipeline analytics which identifies the front runners of all therapeutic areas. It also identifies the potential market movers and future regulatory landscape.

The Report insight covers therapy areas like; Oncology, Central nervous system, Genetic Disorders, Hematological disorders, Metabolic disorders, Ophthalmology, Cardiovascular disease, Respiratory and Immunology and many more…

DelveInsight’s Gene Therapy Reports are available for booking immediately after pre-launch so hurry up book your report and get 1 year subscription for the quarterly updated Gene therapy Report for free by paying additional amount of USD 500. Claim The Offer

For more information contact Website: www.delveinsight.com

Email: info@delveinsight.com

Phone Number: +91-11-4568 9769, +91 9650213330